Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
01
Overview
GS-2278: sourced facts only. name: "Through modification of the sulfonamide, 42 (GS-2278) emerged as a potent LPAR1 antagonist with a suitable in vitro profile and desirable pharmacokinetic properties for oral QD dosing." [PMID:39570661]; target: "Through modification of the sulfonamide, 42 (GS-2278) emerged as a potent LPAR1 antagonist with a suitable in vitro profile and desirable pharmacokinetic properties for oral QD dosing." [PMID:39570661]; developer: "Gilead Sciences Inc., 333 Lakeside Drive, Foster City, California 94404, United States." [PMID:39570661]; stage: "GS-2278 dose-dependently blocked LPA-induced histamine release and demonstrated efficacy in an interventional model of bleomycin-induced lung fibrosis." [PMID:39570661]
02
Targets
LPAR1 (Lysophosphatidic acid receptor 1)
Beyond the preview
Go deeper on GS-2278.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on GS-2278.